Advertisement

Journal of Molecular Medicine

, Volume 85, Issue 7, pp 697–706 | Cite as

Roles of PPARs on regulating myocardial energy and lipid homeostasis

  • Qinglin YangEmail author
  • Yuhao Li
Review

Abstract

Myocardial energy and lipid homeostasis is crucial for normal cardiac structure and function. Either shortage of energy or excessive lipid accumulation in the heart leads to cardiac disorders. Peroxisome proliferator-activated receptors (PPARα, -β/δ and -γ), members of the nuclear receptor transcription factor superfamily, play important roles in regulating lipid metabolic genes. All three PPAR subtypes are expressed in cardiomyocytes. PPARα has been shown to control transcriptional expression of key enzymes that are involved in fatty acid (FA) uptake and oxidation, triglyceride synthesis, mitochondrial respiration uncoupling, and glucose metabolism. Similarly, PPARβ/δ is a transcriptional regulator of FA uptake and oxidation, mitochondrial respiration uncoupling, and glucose metabolism. On the other hand, the role of PPARγ on transcriptional regulation of FA metabolism in the heart remains obscure. Therefore, both PPARα and PPARβ/δ are important transcriptional regulators of myocardial energy and lipid homeostasis. Moreover, it appears that the heart needs to have two PPAR subtypes with seemingly overlapping functions in maintaining myocardial lipid and energy homeostasis. Further studies on the potential distinctive roles of each PPAR subtype in the heart should provide new therapeutic targets for treating heart disease.

Keywords

Lipid metabolism Bioenergetics PPARα PPARβ/δ PPARγ 

Notes

Acknowledgments

This work was partially supported by grants from the NIH (S06GM08248 and 1R01HL085499-01), a scientist development award from the American Heart Association national center, and an institutional grant from NIH (NIH/NIHGMS S). We thank Kevin Yang for editing and proofreading the manuscript.

References

  1. 1.
    Kliewer SA, Xu HE, Lambert MH, Willson TM (2001) Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56:239–263PubMedCrossRefGoogle Scholar
  2. 2.
    Iemitsu M, Miyauchi T, Maeda S, Tanabe T, Takanashi M, Irukayama-Tomobe Y, Sakai S, Ohmori H, Matsuda M, Yamaguchi I (2002) Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 283:H1750–H1760PubMedGoogle Scholar
  3. 3.
    Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384:39–43PubMedCrossRefGoogle Scholar
  4. 4.
    Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819PubMedCrossRefGoogle Scholar
  5. 5.
    van der Vusse GJ, Glatz JF, Stam HC, Reneman RS (1992) Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 72:881–940PubMedGoogle Scholar
  6. 6.
    Vary TC, Reibel DK, Neely JR (1981) Control of energy metabolism of heart muscle. Annu Rev Physiol 43:419–430PubMedCrossRefGoogle Scholar
  7. 7.
    Neely JR, Rovetto MJ, Oram JF (1972) Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15:289–329PubMedCrossRefGoogle Scholar
  8. 8.
    Yang Q, Cheng LH (2005) Molecular regulation of lipotoxicity in the heart. Drug Discov Today 2:101–107CrossRefGoogle Scholar
  9. 9.
    Kelly DP, Strauss AW (1994) Inherited cardiomyopathies. N Engl J Med 330:913–919PubMedCrossRefGoogle Scholar
  10. 10.
    Wittels B, Spann JF Jr (1968) Defective lipid metabolism in the failing heart. J Clin Invest 47:1787–1794PubMedGoogle Scholar
  11. 11.
    Massie BM, Schaefer S, Garcia J, McKirnan MD, Schwartz GG, Wisneski JA, Weiner MW, White FC (1995) Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation 91:1814–1823PubMedGoogle Scholar
  12. 12.
    Bishop SP, Altschuld RA (1970) Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 218:153–159PubMedGoogle Scholar
  13. 13.
    Christe ME, Rodgers RL (1994) Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 26:1371–1375PubMedCrossRefGoogle Scholar
  14. 14.
    Takeyama D, Kagaya Y, Yamane Y, Shiba N, Chida M, Takahashi T, Ido T, Ishide N, Takishima T (1995) Effects of chronic right ventricular pressure overload on myocardial glucose and free fatty acid metabolism in the conscious rat. Cardiovasc Res 29:763–767PubMedCrossRefGoogle Scholar
  15. 15.
    Taegtmeyer H, Overturf ML (1988) Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 11:416–426PubMedGoogle Scholar
  16. 16.
    Corr PB, Creer MH, Yamada KA, Saffitz JE, Sobel BE (1989) Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 83:927–936PubMedGoogle Scholar
  17. 17.
    Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97:1784–1789PubMedCrossRefGoogle Scholar
  18. 18.
    Regan TJ, Weisse AB (1992) Diabetic cardiomyopathy. J Am Coll Cardiol 19:1165–1166PubMedCrossRefGoogle Scholar
  19. 19.
    Zoneraich S, Mollura JL (1993) Diabetes and the heart: state of the art in the 1990s. Can J Cardiol 9:293–299PubMedGoogle Scholar
  20. 20.
    Kenno KA, Severson DL (1985) Lipolysis in isolated myocardial cells from diabetic rat hearts. Am J Physiol 249:H1024–H1030PubMedGoogle Scholar
  21. 21.
    Denton RM, Randle PJ (1967) Measurement of flow of carbon atoms from glucose and glycogen glucose to glyceride glycerol and glycerol in rat heart and epididymal adipose tissue. Effects of insulin, adrenaline and alloxan-diabetes. Biochem J 104:423–434PubMedGoogle Scholar
  22. 22.
    Paulson DJ, Crass MF 3rd (1982) Endogenous triacylglycerol metabolism in diabetic heart. Am J Physiol 242:H1084–H1094PubMedGoogle Scholar
  23. 23.
    Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T (2000) Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 275:22293–22299PubMedCrossRefGoogle Scholar
  24. 24.
    Cheng L, Ding G, Qin Q, Xiao Y, Woods D, Chen YE, Yang Q (2004) Peroxisome proliferator-activated receptor [delta] activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun 313:277–286PubMedCrossRefGoogle Scholar
  25. 25.
    Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M (2003) Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518–524PubMedCrossRefGoogle Scholar
  26. 26.
    Mukherjee R, Jow L, Croston GE, Paterniti JR Jr (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272:8071–8076PubMedCrossRefGoogle Scholar
  27. 27.
    Mehrabi MR, Haslmayer P, Humpeler S, Strauss-Blasche G, Marktl W, Tamaddon F, Serbecic N, Wieselthaler G, Thalhammer T, Glogar HD, Ekmekcioglu C (2003) Quantitative analysis of peroxisome proliferator-activated receptor gamma (PPARgamma) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy. Eur J Heart Fail 5:733–739PubMedCrossRefGoogle Scholar
  28. 28.
    Xu Y, Gen M, Lu L, Fox J, Weiss SO, Brown RD, Perlov D, Ahmad H, Zhu P, Greyson C, Long CS, Schwartz GG (2005) PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 288:H1314–H1323PubMedCrossRefGoogle Scholar
  29. 29.
    Liu LS, Tanaka H, Ishii S, Eckel J (1998) The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology 139:4531–4539PubMedCrossRefGoogle Scholar
  30. 30.
    Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM (2005) Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97:372–379PubMedCrossRefGoogle Scholar
  31. 31.
    Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121–130PubMedCrossRefGoogle Scholar
  32. 32.
    Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10:1245–1250PubMedCrossRefGoogle Scholar
  33. 33.
    Brinkmann JF, Abumrad NA, Ibrahimi A, van der Vusse GJ, Glatz JF (2002) New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36. Biochem J 367:561–570PubMedCrossRefGoogle Scholar
  34. 34.
    Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE (2005) Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96:225–233PubMedCrossRefGoogle Scholar
  35. 35.
    Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354–366PubMedCrossRefGoogle Scholar
  36. 36.
    Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP (1998) A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 102:1083–1091PubMedGoogle Scholar
  37. 37.
    Leone TC, Weinheimer CJ, Kelly DP (1999) A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96:7473–7478PubMedCrossRefGoogle Scholar
  38. 38.
    Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103:1489–1498PubMedGoogle Scholar
  39. 39.
    Brandt JM, Djouadi F, Kelly DP (1998) Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 273:23786–23792PubMedCrossRefGoogle Scholar
  40. 40.
    Stavinoha MA, RaySpellicy JW, Essop MF, Graveleau C, Abel ED, Hart-Sailors ML, Mersmann HJ, Bray MS, Young ME (2004) Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated receptor-alpha-regulated gene in cardiac and skeletal muscle. Am J Physiol Endocrinol Metab 287:E888–E895PubMedCrossRefGoogle Scholar
  41. 41.
    Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD (2002) A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277:4098–4103PubMedCrossRefGoogle Scholar
  42. 42.
    Lu B, Jiang YJ, Zhou Y, Xu FY, Hatch GM, Choy PC (2005) Cloning and characterization of murine 1-acyl-sn-glycerol 3-phosphate acyltransferases and their regulation by PPARalpha in murine heart. Biochem J 385:469–477PubMedCrossRefGoogle Scholar
  43. 43.
    Vance JE, Vance DE (1985) The role of phosphatidylcholine biosynthesis in the secretion of lipoproteins from hepatocytes. Can J Biochem Cell Biol 63:870–881PubMedCrossRefGoogle Scholar
  44. 44.
    Murphy DJ, Vance J (1999) Mechanisms of lipid-body formation. Trends Biochem Sci 24:109–115PubMedCrossRefGoogle Scholar
  45. 45.
    Yamaguchi T, Matsushita S, Motojima K, Hirose F, Osumi T (2006) MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor alpha. J Biol Chem 281:14232–14240PubMedCrossRefGoogle Scholar
  46. 46.
    Boren J, Veniant MM, Young SG (1998) Apo B100-containing lipoproteins are secreted by the heart. J Clin Invest 101:1197–1202PubMedGoogle Scholar
  47. 47.
    Veniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG (1998) Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J Clin Invest 102:1559–1568PubMedCrossRefGoogle Scholar
  48. 48.
    McCormick SP, Ng JK, Veniant M, Boren J, Pierotti V, Flynn LM, Grass DS, Connolly A, Young SG (1996) Transgenic mice that overexpress mouse apolipoprotein B. Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene. J Biol Chem 271:11963–11970PubMedCrossRefGoogle Scholar
  49. 49.
    Nielsen LB, Veniant M, Boren J, Raabe M, Wong JS, Tam C, Flynn L, Vanni-Reyes T, Gunn MD, Goldberg IJ, Hamilton RL, Young SG (1998) Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation 98:13–16PubMedGoogle Scholar
  50. 50.
    Nielsen LB, Bartels ED, Bollano E (2002) Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice. J Biol Chem 277:27014–27020PubMedCrossRefGoogle Scholar
  51. 51.
    Bjorkegren J, Veniant M, Kim SK, Withycombe SK, Wood PA, Hellerstein MK, Neese RA, Young SG (2001) Lipoprotein secretion and triglyceride stores in the heart. J Biol Chem 276:38511–38517PubMedCrossRefGoogle Scholar
  52. 52.
    Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, Goldberg IJ (2004) Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 279:4204–4211PubMedCrossRefGoogle Scholar
  53. 53.
    Ameen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, Tuneld A, Olofsson SO, Linden D, Oscarsson J (2005) Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem 280:1224–1229PubMedCrossRefGoogle Scholar
  54. 54.
    Taegtmeyer H (2002) Switching metabolic genes to build a better heart. Circulation 106:2043–2045PubMedCrossRefGoogle Scholar
  55. 55.
    Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H (2001) Metabolic gene expression in fetal and failing human heart. Circulation 104:2923–2931PubMedGoogle Scholar
  56. 56.
    Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP (1996) Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94:2837–2842PubMedGoogle Scholar
  57. 57.
    Sack MN, Disch DL, Rockman HA, Kelly DP (1997) A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci USA 94:6438–6443PubMedCrossRefGoogle Scholar
  58. 58.
    Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJ, Taegtmeyer H (1998) Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 4:1269–1275PubMedCrossRefGoogle Scholar
  59. 59.
    Young ME, Laws FA, Goodwin GW, Taegtmeyer H (2001) Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276:44390–44395PubMedCrossRefGoogle Scholar
  60. 60.
    Barger PM, Kelly DP (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10:238–245PubMedCrossRefGoogle Scholar
  61. 61.
    Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, World MJ, Doering A, Erdmann J, Hengstenberg C, Humphries SE, Schunkert H, Flavell DM (2002) Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105:950–955PubMedCrossRefGoogle Scholar
  62. 62.
    Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. Faseb J 16:1027–1040PubMedCrossRefGoogle Scholar
  63. 63.
    Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I (2002) Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 103 (Suppl 48):284S–288SGoogle Scholar
  64. 64.
    Sakai S, Miyauchi T, Irukayama-Tomobe Y, Ogata T, Goto K, Yamaguchi I (2002) Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 103 (Suppl 48):16S–20SGoogle Scholar
  65. 65.
    Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA (2002) Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106:606–612PubMedCrossRefGoogle Scholar
  66. 66.
    Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, Vazquez-Carrera M (2005) Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65:832–841PubMedCrossRefGoogle Scholar
  67. 67.
    Ding G, Cheng L, Qin Q, Frontin S, Yang Q (2006) PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40:821–828PubMedCrossRefGoogle Scholar
  68. 68.
    Larsen TM, Toubro S, Astrup A (2003) PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 27:147–161PubMedCrossRefGoogle Scholar
  69. 69.
    Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, Gonzalez FJ (2003) Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111:737–747PubMedCrossRefGoogle Scholar
  70. 70.
    Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J (2003) Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9:1491–1497PubMedCrossRefGoogle Scholar
  71. 71.
    Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR (2003) Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608–618PubMedCrossRefGoogle Scholar
  72. 72.
    Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7355–7359PubMedCrossRefGoogle Scholar
  73. 73.
    Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I (2002) Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240–1246PubMedCrossRefGoogle Scholar
  74. 74.
    Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K (2001) Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104:1670–1675PubMedGoogle Scholar
  75. 75.
    Nemoto S, Razeghi P, Ishiyama M, De Freitas G, Taegtmeyer H, Carabello BA (2005) PPAR-gamma agonist, rosiglitazone, ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol Heart Circ Physiol 288(1):H77–H82PubMedCrossRefGoogle Scholar
  76. 76.
    Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A (2002) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106:3126–3132PubMedCrossRefGoogle Scholar
  77. 77.
    Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A (2002) Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51:1507–1514PubMedCrossRefGoogle Scholar
  78. 78.
    Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104:2588–2594Google Scholar
  79. 79.
    Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA (2004) Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 308:426–433PubMedCrossRefGoogle Scholar
  80. 80.
    Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861–866PubMedCrossRefGoogle Scholar
  81. 81.
    Mann DL, Young JB (1994) Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105:897–904PubMedGoogle Scholar
  82. 82.
    Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85:1093–1129PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Cardiovascular Research InstituteMorehouse School of MedicineAtlantaUSA
  2. 2.Department of Medicine and Clinical ScienceKyoto University Graduate School of MedicineKyotoJapan
  3. 3.Faculty of Pharmacy A15The University of SydneySydneyAustralia

Personalised recommendations